全身α1肾上腺素受体拮抗剂与开角型青光眼风险增加:一项全国性人群队列研究
该研究基于台湾地区百万人随机抽样数据库,纳入2001至2012年诊断为下尿路症状的105,341人,经倾向评分匹配后比较4,081例使用α1肾上腺素受体拮抗剂者与4,081例未使用者。结果显示用药组开角型青光眼发病率比为1.86(95%CI 1.30-2.65),校正后风险比1.66(95%CI 1.16-2.39;P=0.006),高血压患者中风险比升至1.79(95%CI 1.07-2.99;P=0.003),而在糖尿病、高脂血症或老年患者中关联不显著。
要点
- 使用α1肾上腺素受体拮抗剂的下尿路症状患者开角型青光眼风险显著增加,校正后HR为1.66。
- 高血压患者中该关联更强,HR为1.79(95%CI 1.07-2.99;P=0.003)。
- 糖尿病、高脂血症或老年患者中未观察到显著关联。
核心结论
- 使用α1肾上腺素受体拮抗剂治疗下尿路症状的患者开角型青光眼风险增加,尤其在高血压患者中更为明显。
研究设计与样本
- 经1:1倾向评分匹配性别、年龄、合并疾病、观察期内就诊次数和索引日期后,纳入4,081例使用α1肾上腺素受体拮抗剂者与4,081例未使用者。
主要发现
- 使用α1肾上腺素受体拮抗剂者开角型青光眼发病率比为1.86(95%CI 1.30-2.65)。
- 校正年龄、性别和合并疾病后,开角型青光眼风险比(HR)为1.66(95%CI 1.16-2.39;P=0.006)。
- 高血压患者中使用α1肾上腺素受体拮抗剂与开角型青光眼相关的HR为1.79(95%CI 1.07-2.99;P=0.003)。
- 在糖尿病、高脂血症或老年患者中,α1肾上腺素受体拮抗剂与开角型青光眼的关联不显著。
关键数值与推荐
- 开角型青光眼定义为两次门诊就诊记录ICD-9诊断码365,排除365.2-365.6、365.02、365.03、365.13、365.14和365.8。
临床怎么用
- 对使用α1肾上腺素受体拮抗剂治疗下尿路症状的患者,尤其合并高血压者,应关注开角型青光眼风险并考虑眼科评估。
- 在糖尿病、高脂血症或老年患者中,该关联不显著,但仍需结合个体情况判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To examine the risk of open-angle glaucoma (OAG) among patients receiving alpha1-adrenoceptor (α1-AR) antagonists for lower urinary tract symptoms (LUTS). METHODS: This was a nationwide, population-based, retrospective cohort study from Asia/Taiwan. One million beneficiaries were randomly sampled from among 27.38 million individuals enrolled in the National Health Insurance program, and subjects with a diagnosis of LUTS from 2001 to 2012 were identified (N = 105,341). After 1:1 propensity score matching by gender, age, comorbid medical diseases, number of all medical visits during the observational period, and index date, 4081 patients were enrolled in the study group, comprised of patients who had taken α1-AR antagonists, and 4081 patients were enrolled in the control group, comprised of patients who had never taken α1-AR antagonists. The incidence and risk of OAG (defined as two ambulatory visits with a ICD-9 diagnosis code 365, excluding ICD-9 diagnosis codes 365.2-365.6, 365.02, 365.03, 365.13, 365.14, and 365.8) were calculated. RESULTS: Patients taking α1-AR antagonists had a higher incidence ratio of 1.86 (95% confidence interval [CI], 1.30-2.65) for developing OAG. After adjusting for age, gender, and comorbidities, the hazard ratio (HR) for OAG for patients taking α1-AR antagonists was 1.66 (95% CI, 1.16-2.39; P = 0.006). Among patients with hypertension, the hazard ratio for OAG associated with taking α1-AR antagonists increased to 1.79 (95% CI, 1.07-2.99; P = 0.003). On the other hand, the association of α1-AR antagonists with OAG was not significant among patients with diabetes mellitus, hyperlipidemia, or older age. CONCLUSIONS: The findings of our study suggest an increased risk for OAG among patients taking α1-AR antagonists for LUTS, especially in patients with hypertension.
引用
- Lin HZ, Hsieh TC, Wu JL, et al. Systemic Alpha1-Adrenoceptor Antagonists and Increased Risk of Open-Angle Glaucoma: A Nationwide Population-Based Cohort Study. Invest Ophthalmol Vis Sci. 2020. PMID: 32766746. doi:10.1167/iovs.61.10.15
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。